Physician profile
Joyce E Vacek
NPI 1285791186
$6,941.86
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $595 · 2022: $3,556 · 2023: $1,374 · 2024: $1,417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,790.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,379.86 | 2021-2024 | |
| Aimmune Therapeutics, INC. | $578.70 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $373.42 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $328.73 | 2021-2024 | |
| Amgen INC. | $252.48 | 2021-2024 | Prolia, Evenity |
| Novo Nordisk INC | $203.57 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $153.86 | 2022-2023 | Trelegy Ellipta, Bexsero, Pediarix |
| Gilead Sciences, INC. | $145.24 | 2022-2024 | |
| Lilly USA, LLC | $144.60 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Janssen Pharmaceuticals, INC | $143.81 | 2021-2024 | Xarelto |
| Nestle Healthcare Nutrition INC. | $143.51 | 2023 | |
| Ironwood Pharmaceuticals, INC | $110.23 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $102.16 | 2022-2024 | |
| Corcept Therapeutics | $94.21 | 2022-2023 | Korlym |
| Pfizer INC. | $85.42 | 2021-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $75.61 | 2021-2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.28 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $59.78 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $55.91 | 2021-2024 | Dificid |
| Biohaven Pharmaceutical Holding Company LTD. | $55.19 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.59 | 2021-2023 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $52.85 | 2023 | Austedo |
| Lexicon Pharmaceuticals, INC. | $48.04 | 2023-2024 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.14 | 2021-2022 | |
| Astellas Pharma US INC | $37.27 | 2021-2024 | Veozah |
| Exact Sciences Corporation | $31.24 | 2023 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $30.69 | 2021 | |
| Neos Therapeutics, LP | $19.02 | 2022 | |
| Avanir Pharmaceuticals, INC. | $15.12 | 2022 | |
| Insulet Corporation | $14.82 | 2023 | Omnipod |
| Genentech USA, INC. | $13.35 | 2021 | |
| Eisai INC. | $12.22 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.03 | 2021 | |
| Sumitomo Pharma America, INC. | $11.91 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Vacek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.